Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists

Elucidation of the cellular and molecular mediators of tissue injury in Crohn’s disease (CD) and ulcerative colitis (UC) has expanded the potential management options for these diseases. The discovery of immunologic and inflammatory mediators, in particular, has paved the way for clinical research with biologic agents in this area. Although conventional treatments remain viable options for some patients, those who are intolerant to these agents and those with more serious or refractory disease may require newer biologic therapies.